<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612335</url>
  </required_header>
  <id_info>
    <org_study_id>NL73104.068.20</org_study_id>
    <nct_id>NCT04612335</nct_id>
  </id_info>
  <brief_title>Device-based Rate Versus Rhythm Control in Symptomatic Recent-onset Atrial Fibrillation (RACE 9 OBSERVE-AF)</brief_title>
  <official_title>Device-based Rate Versus Rhythm Control Treatment in Patients With Symptomatic Recent-onset Atrial Fibrillation in the Emergency Department (RACE 9 OBSERVE-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Netherlands Organisation for Scientific Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous heart rhythm monitoring elucidated the recurrent and transient nature of&#xD;
      recent-onset atrial fibrillation (AF). The RACE7 ACWAS showed that a wait-and-see approach&#xD;
      (WAS) in patients with recent-onset AF (rate control for symptom relief followed by delayed&#xD;
      cardioversion if needed &lt;48h) allows spontaneous conversion to sinus rhythm in 69% of&#xD;
      patients, obviating active cardioversion. Recurrences within one month were seen in 30% of&#xD;
      patients in both groups, i.e. the initially chosen strategy did not affect the recurrence&#xD;
      pattern. Considering the latter, it remains unclear whether cardioversion is needed at all,&#xD;
      especially since cardioversion strategy does not seem to affect behaviour of the arrhythmia&#xD;
      over time. Instead of cardioversion a watchful-waiting rate control strategy may be&#xD;
      appropriate as initial strategy. This allows observing the electrical and clinical behavior&#xD;
      of arrhythmia, providing a solid basis for comprehensive and effective early rhythm control.&#xD;
      This study is a multi-center clinical randomized controlled trial to show non-inferiority of&#xD;
      watchful-waiting with rate control versus routine care in terms of prevalence of sinus rhythm&#xD;
      at 4 weeks follow-up, using a novel telemonitoring infrastructure to guide rate control&#xD;
      during follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until recently standard of care for patients with recent-onset atrial fibrillation (AF) was&#xD;
      early cardioversion. This has just been expanded with a delayed cardioversion approach.&#xD;
      However, considering the recurrent and transient nature of AF, cardioversion might not be&#xD;
      needed at all and rate control medication might be sufficient to accomplish spontaneous&#xD;
      conversion to sinus rhythm. The aim of this trial is to evaluate effectiveness (presence of&#xD;
      sinus rhythm) of a watchful-waiting approach, i.e. symptom reduction through rate-control&#xD;
      medication and monitoring until spontaneous conversion is achieved compared to routine care,&#xD;
      consisting of either early or delayed cardioversion. The trial is a multicentre prospective,&#xD;
      randomized, open label, non-inferiority trial comparing the interventional watchful-waiting&#xD;
      approach to routine care (control).The primary endpoint (presence of sinus rhythm), will be&#xD;
      assessed after 4 weeks. The total follow-up time is 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of sinus rhythm</measure>
    <time_frame>4 weeks after inclusion</time_frame>
    <description>Sinus rhythm documented on a 12-lead ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implementation of the telemonitoring infrastructure</measure>
    <time_frame>4 weeks</time_frame>
    <description>e.g. use of telemonitoring infrastructure during the 4 weeks follow up, accuracy of alert system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE: major cardiovascular mortality and cardiovascular and cerebrovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>e.g. hospitalisation for stroke, myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF recurrences/AF progression</measure>
    <time_frame>4 weeks and 1 year</time_frame>
    <description>e.g. number of AF recurrences, progression to persistent AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>1 year</time_frame>
    <description>The costs and cost-effectiveness of the new approach will be determined and compared to the costs and cost-effectiveness of routine care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires on quality of life (SF-36)</measure>
    <time_frame>1 year</time_frame>
    <description>Questionnaires on quality of life (e.g. SF-36), will be used to assess whether there are differences between the two arms. The SF-36 will be evaluated according to recommendations; scores will be recoded on a scale of 0-100 and averaged. Higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported experiences</measure>
    <time_frame>1 year</time_frame>
    <description>A questionnaire on patient reported experiences with the telemonitoring device will be used to assess whether there are differences between the two arms. There will be both positively orientated, and negatively orientated questionnes which have to be rated on a scale of 1-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and rhythm control interventions (number of)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Alert- and patient-triggered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythm control interventions</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with cardioversion, catheter ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Watchful waiting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate &lt;110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rate control</intervention_name>
    <description>Rate control drugs are administered to obtain symptom relief and a heart rate of &lt;110 bpm, followed by a 4-week telemonitoring period.</description>
    <arm_group_label>Watchful waiting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological or electrical cardioversion</intervention_name>
    <description>Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.</description>
    <arm_group_label>Routine care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECG with atrial fibrillation&#xD;
&#xD;
          -  Duration of the current AF episode &lt;36 hours&#xD;
&#xD;
          -  Symptoms due to atrial fibrillation&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Able and willing to sign informed consent&#xD;
&#xD;
          -  Able and willing to use telemetric rhythm recorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of persistent AF (episode of AF lasting more than 48 hours and terminated by&#xD;
             cardioversion)&#xD;
&#xD;
          -  Deemed unsuitable for participation by attending physician&#xD;
&#xD;
          -  Hemodynamic instability (heart rate &gt;170 bpm, systolic blood pressure &lt;100 mmHg)&#xD;
&#xD;
          -  Acute heart failure&#xD;
&#xD;
          -  Signs of myocardial infarction&#xD;
&#xD;
          -  History of syncope of unexplained origin&#xD;
&#xD;
          -  History of untreated Sick Sinus Syndrome&#xD;
&#xD;
          -  History of untreated Wolff-Parkinson-White syndrome&#xD;
&#xD;
          -  Currently enrolled in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry JG Crijns, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of cardiology department, Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Linz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of cardiac electrophysiology, Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel MJ van der Velden, MD</last_name>
    <phone>31433876885</phone>
    <email>rachel.vander.velden@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki AH Pluymaekers, MD</last_name>
    <phone>31433875119</phone>
    <email>nikki.pluymaekers@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel van der Velden, MD</last_name>
      <phone>+31433876885</phone>
      <email>rachel.vander.velden@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O Kamp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Hemels</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Opstal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Tieleman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I van Gelder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T Lenderink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Kirchhof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V van Dijk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Beukema</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Oomen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Widdershoven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Centre</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Heesen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <keyword>Cardioversion</keyword>
  <keyword>Electrical cardioversion</keyword>
  <keyword>Watchful waiting</keyword>
  <keyword>Wait-and-see</keyword>
  <keyword>Telemonitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All elements from the CRF matching a future project's CRF may be provided for an aggregated analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Well after publication of main paper</ipd_time_frame>
    <ipd_access_criteria>Please contact principal investigator or study chair.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

